1187964-14-2

Upstream product

• 1187964-13-1 (E)-ethyl 3-(1,4-dioxaspiro[4.5]decan-8-yl)acrylate 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 

Downstream Products

• 58012-66-1 3-(4-oxocyclohexyl)propionic acid ethyl ester 

Relevant academic research and scientific papers

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

BICYCLIC HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Bicyclic heteroaryl derivatives of Formula 1, and pharmaceutically acceptable salts, isomers, hydrates and solvates thereof can selectively and effectively inhibit DGAT1, and thus can be useful as medicines for effectively treating dangerous diseases such as obesity, type 2 diabetes, abnormal lipidemia, metabolic syndrome (syndrome X) and the like, which are caused by DGAT1, with no adverse side effects.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to the formula I: processes for the preparation thereof, pharmaceutical composition containing these compounds and the use of substituted sulfonamide compounds for the preparation of pharmaceutical compositions.